<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kuznar, Wayne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">McInnes, Iain B.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Inhibitor of Interleukins 12 and 23 Slows Joint Destruction in Psoriatic Arthritis</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-01-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">15-16</style></pages><abstract><style  face="normal" font="default" size="100%">A prespecified integrated analysis of two Phase 3 clinical trials demonstrates that the monoclonal antibody ustekinumab reduces radiographic progression of joint disease in patients with active psoriatic arthritis. This article presents the integrated analysis of the two Phase 3 Multicenter, Randomised, Double-Blind, Placebo-Controlled Trials of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriasis Arthritis [PSUMMIT I and II; NCT01009086; NCT01077362].</style></abstract><number><style face="normal" font="default" size="100%">18</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>